X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NFL-101 (tobacco leaf protein) is a nicotine-free botanical drug candidate, comprising natural proteins extracted from tobacco leaves. It is being evaluated for reduction in the desire to smoke, without any toxicity which also reduces tobacco allergies.
Lead Product(s): Tobacco Leaf Extract
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
NFL-101 (tobacco leaf protein) is a nicotine-free botanical drug candidate, comprising natural proteins extracted from tobacco leaves. It is under phase I trials, for reduction in the desire to smoke, without any toxicity which also reduces tobacco allergies.
Lead Product(s): Tobacco Leaf Protein
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
The funding will be used to complete the CESTO II clinical study designed to evaluate the efficacy and safety of its NFL-101 (tobacco leaf protein) treatment as a smoking cessation therapy.
Lead Product(s): NFL-101
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $1.8 million Upfront Cash: Undisclosed
Deal Type: Funding February 20, 2023
Details:
Under the terms of the collaboration, NFL-Biosciences will use the CEA's molecular imaging resources to better understand the mechanism of action of NFL 101. NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families.
Lead Product(s): NFL-101
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CEA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 02, 2023
Details:
The funding will be used for the CESTO II phase II/III trial, aiming to demonstrate the efficacy of its botanical drug candidate NFL-101 for smoking cessation and and the PRECESTO trial, assessing the potential of NFL-101 for nicotine replacement therapies.
Lead Product(s): NFL-101
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Financing January 30, 2023
Details:
NFL-101 (tobacco leaf protein) is a nicotine-free botanical drug candidate, comprising natural proteins extracted from tobacco leaves. It is under phase I trials, for reduction in the desire to smoke, without any toxicity which also reduces tobacco allergies.
Lead Product(s): Tobacco Leaf Protein
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
NFL-101 is a standardized, nicotine-free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative.
Lead Product(s): Tobacco Leaf Protein
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: French Government
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Funding January 11, 2023
Details:
NFL-101, is a standardized, nicotine-free tobacco leaf extract protected by two patent families, intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative.
Lead Product(s): Tobacco Leaf Protein
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
Under the partnership to develop NFL-101, the company’s drug candidate Tobacco leaf protein for smoking cessation, for the Indian market with Themis Medicare Ltd., will purchase Active Pharmaceutical Ingredient (API) from NFL Biosciences.
Lead Product(s): Tobacco Leaf Protein
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Artemis Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 05, 2022
Details:
NFL-101 (tobacco leaf protein), is a natural product based on a standardized extract of tobacco leaf patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit.
Lead Product(s): Tobacco Leaf Protein
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
